This study investigated whether ivabradine, a selective If current inhibitor reducing heart rate (HR), is able to improve survival and prevent left ventricular (LV) remodeling in isoproterenol-induced heart damage. Wistar rats were treated for 6 weeks: controls (n = 10), ivabradine (10 mg/kg/day orally; n = 10), isoproterenol (5 mg/kg/day intraperitoneally; n = 40), and isoproterenol plus ivabradine (n = 40). Isoproterenol increased mortality, induced hypertrophy of both ventricles and LV fibrotic rebuilding, and reduced systolic blood pressure (SBP). Ivabradine significantly increased survival rate (by 120%) and prolonged average survival time (by 20%). Furthermore, ivabradine reduced LV weight and hydroxyproline content in soluble and insoluble collagen fraction, reduced HR and attenuated SBP decline. We conclude that ivabradine improved survival in isoproterenol-damaged hearts.

3rd Department of Internal Medicine Faculty of Medicine Comenius University Bratislava 83305 Slovak Republic

Department of Physiology School of Medicine Charles University Hradec Kralove 50003 Czech Republic

Institute of Experimental Endocrinology Biomedical Research Center Slovak Academy of Sciences Bratislava 84505 Slovak Republic

Institute of Pathophysiology Faculty of Medicine Comenius University Bratislava 81108 Slovak Republic

See more in PubMed

Simko F., Bednarova K.R., Krajcirovicova K. et al. Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol‐induced heart failure. J. Pineal. Res. (2014) 57 177–184. PubMed

Swedberg K., Komajda M., Böhm M. et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo‐controlled study. Lancet (2010) 376 875–885. PubMed

McMurray J.J.It is BEAUTIFUL we should be concerned about, not SIGNIFY: is ivabradine less effective in ischaemic compared with non‐ischaemic LVSD? Eur. Heart J. (2015) 36 2047–2049. PubMed

Simko F., Baka T., Poglitsch M. et al. Effect of ivabradine on a hypertensive heart and the renin‐angiotensin‐aldosterone system in L‐NAME‐induced hypertension. Int. J. Mol. Sci. (2018) 19 pii: E3017. PubMed PMC

Rathinavel A., Sankar J., Mohammed Sadullah S.S., Niranjali Devaraj S.Oligomeric proanthocyanidins protect myocardium by mitigating left ventricular remodeling in isoproterenol‐induced postmyocardial infarction. Fundam. Clin. Pharmacol. (2018) 32 51–59. PubMed

Refaie M.M.M., Rifaai R.A., Bayoumi A.M.A., Shehata S.Cardioprotective effect of hemin in isoprenaline‐induced myocardial infarction: role of ATP‐sensitive potassium channel and endothelial nitric oxide synthase. Fundam. Clin. Pharmacol. (2020) 34 302–312. PubMed

Dedkov E.I., Zheng W., Christensen L.P., Weiss R.M., Mahlberg‐Gaudin F., Tomanek R.J.Preservation of coronary reserve by ivabradine‐induced reduction in heart rate in infarcted rats is associated with decrease in perivascular collagen. Am. J. Physiol. Heart Circ. Physiol. (2007) 293 H590–H598. PubMed

Busseuil D., Shi Y., Mecteau M. et al. Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis. Cardiology (2010) 117 234–242. PubMed

Doesch A.O., Mueller S., Erbel C. et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long‐term follow‐up study. Drug Des. Devel. Ther. (2013) 7 1323–1328. PubMed PMC

Milliez P., Messaoudi S., Nehme J., Rodriguez C., Samuel J.L., Delcayre C.Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am. J. Physiol. Heart Circ. Physiol. (2009) 296 H435–H441. PubMed

Kim B.H., Cho K.I., Kim S.M. et al. Heart rate reduction with ivabradine prevents thyroid hormone‐induced cardiac remodeling in rat. Heart Vessels. (2013) 28 524–535. PubMed

Borer J.S., Deedwania P.C., Kim J.B., Böhm M.Benefits of heart rate slowing with ivabradine in patients with systolic heart failure and coronary artery disease. Am. J. Cardiol. (2016) 118 1948–1953. PubMed

Heusch G., Kleinbongard P.Ivabradine: cardioprotection by and beyond heart rate reduction. Drugs (2016) 76 733–740. PubMed

Camici P.G., Gloekler S., Levy B.I. et al. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction. Int. J. Cardiol. (2016) 215 1–6. PubMed

Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin-Angiotensin-Aldosterone System